VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | ERd in the treatment of newly diagnosed MM

Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, discusses a phase II study (NCT02843074) to assess the feasibility and tolerance of the combination of elotuzumab, lenalidomide and dexamethasone (ERd) in the induction, consolidation and maintenance treatment of patients with transplant-eligible newly diagnosed multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter